Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Brain Tumor Drugs Market CAGR Outlook And Future Development
The brain tumor drugs market size has grown strongly in recent years. Its value is expected to rise from $4.03 billion in 2025 to $4.26 billion in 2026, registering a compound annual growth rate (CAGR) of 5.7%. This notable growth during the preceding period stemmed from an increasing prevalence of brain tumors, significant advancements in chemotherapy drugs, heightened awareness regarding symptom management, the progression of hormone therapies, and the introduction of new anticonvulsants.
The brain tumor drugs market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $5.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this projected growth include the advancement of precision medicine, the incorporation of artificial intelligence in drug discovery efforts, broadened research and development in oncology, heightened healthcare spending, and the increasing uptake of targeted therapies. Key trends identified for the forecast period encompass personalized chemotherapy approaches, an increase in hormone therapy applications, the development of advanced pain management medications, a growing reliance on anticonvulsants for symptom management, and the expansion of pipelines for brain tumor drugs.
Get A Free Sample Report With In-Depth Market Insights:
Brain Tumor Drugs Market Growth Backed By Core Demand Fundamentals
A rising count of patients receiving chemotherapy is projected to drive the brain tumor drug market’s expansion. This medical approach utilizes potent medications to target and eliminate rapidly multiplying cells, like cancer cells. Chemotherapy serves as a crucial treatment for brain tumors, with the development and availability of effective drugs significantly boosting overall treatment success. The effectiveness of chemotherapy is vital for prolonging patient survival and enhancing their quality of life, thereby influencing market development. For instance, in July 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in the United States, more than 1 million cancer patients receive chemotherapy or radiation each year. Hence, the growing number of individuals undergoing chemotherapy is fueling the brain tumor drug market’s growth.
Brain Tumor Drugs Market Segment Performance And Emerging Opportunities
The brain tumor drugs market covered in this report is segmented –
1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users
3) By Mechanism of Action: Chemotherapy Agents, Targeted Therapy, Hormone Therapy
Subsegments:
1) By Temozolomide: Oral Formulation, Injectable Formulation
2) By Bevacizumab: Monoclonal Antibody Therapy, Combination Therapy With Chemotherapy
3) By Other Drugs: Carmustine, Lomustine, Etoposide, Irinotecan, Novantrone (Mitoxantrone)
Brain Tumor Drugs Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the brain tumor drugs market are concentrating on technological breakthroughs, such as targeted RAF kinase inhibitors, to meet the increasing demand for precision oncology treatments. These treatments aim to target specific genetic mutations found in brain tumors, thereby reducing systemic toxicity and enhancing patient outcomes. A RAF kinase inhibitor is a medication designed to selectively block the activity of RAF proteins, which are integral to the MAPK signaling pathway, consequently inhibiting the proliferation of tumor cells. This approach differs from traditional chemotherapies, which indiscriminately destroy rapidly dividing cells and frequently cause broader systemic side effects. For example, in November 2025, Day One Biopharmaceuticals, a US-based biotechnology company, introduced OJEMDA (tovorafenib), an innovative therapy for pediatric patients with relapsed or refractory low-grade gliomas containing BRAF fusions or V600 mutations. Tovorafenib is an orally administered, once-weekly, brain-penetrant inhibitor that precisely targets mutant RAF proteins, providing strong central nervous system exposure and a mechanism customized to the tumor’s molecular driver. Its notable attributes include high selectivity, lower systemic toxicity compared to conventional chemotherapy, and its suitability for pediatric patients. This product signifies a considerable advancement in genetically guided therapy for childhood brain tumors.
Brain Tumor Drugs Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the brain tumor drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co. Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.
View The Full Brain Tumor Drugs Market Report:
Brain Tumor Drugs Market Largest Region By Revenue And Market Share
North America was the largest region in the brain tumor drugs market in 2025. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model